Varada Soujanya and Revu Baby Nalanda*

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), India

*Corresponding Author: Revu Baby Nalanda, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), India.

Received: May 24, 2024; Published: May 31, 2024

Abstract

The current investigation was pointed at developing and progressively validating novel, simple, responsive and stable RP-HPLC method for the measurement of active pharmaceutical ingredients of Nirmatrelvir and Ritonavir and their related substances. RP-HPLC methodology was used for the quantitative determination of Nirmatrelvir and Ritonavir. Sunfire C18 Column, (5 μm, 4.6 mm X 250 mm) using mobile phase of 0.01N KH2PO4: Acetonitrile: Methanol (80:20:10 v/v) with flow rate of 1 ml/min (Detection wavelength 238 nm) was used for the present study. Using the impurity-spiked solution, the chromatographic approach was streamlined. The proposed method to be fast, simple, feasible and affordable in RS condition. During stability tests, it can be used for routine analysis of production samples and to verify the quality of drug samples during stability studies.

Keywords: Nirmatrelvir; Ritonavir; Impurities; RP-HPLC; Validation

References

1. Bekerman E and Einav S. “Combating emerging viral threats”. Science 348 (2015): 282-283.
2. Lea AP and Faulds D. “Ritonavir”. Drugs4 (1996): 541-546.
3. Eatemadi A., et al. “Role of protease and protease inhibitors in cancer pathogenesis and treatment”. Biomed Pharmacotherapy 86 (2017): 221-231.
4. Geneva: IFPMA. International Conference on Harmonization. Guidance on validation of analytical procedure: Text and methodology. ICH - Q2 (R1) (2005).
5. Saravolatz LD., et al. “Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs”. Clinical Infectious Disease (2022).
6. Hiremath S., et al. “Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD”. CJASN 8 (2022): 1247-1250.
7. Bioanalytical method validation, European Medicines Agency (2012).
8. Aboras SI and Maher HM. “Green adherent degradation kinetics study of nirmatrelvir, an oral anti-COVID-19: Characterization of degradation products using LC-MS with in silico toxicity profile”. BMC Chemistry1 (2023): 23.
9. ICH, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use ICH harmonized tripartite guideline stability testing of new drug substances and products Q1A (R2) (2003).
10. International Conference on Harmonization. ICH Q2 (R1): Validation of analytical procedures: Text and methodology. ICH Secretariat, Geneva (2005).
11. Patil TS and Deshpande A. “Development of an innovative quality by design (QbD) based stability-indicating HPLC method and its validation for clofazimine from its bulk and pharmaceutical dosage forms”. Chromatographia2 (2019): 579-590.
12. Secretan P., et al. “Unequal behaviour between hydrolysable functions of nirmatrelvir under stress conditions: Structural and theoretical approaches in support of preformulation studies”. Pharmaceutics8 (2022): 1720.

Citation

Citation: Varada Soujanya and Revu Baby Nalanda. “Simultaneous Estimation of Analytical Method Development and Validation of Nirmatrelvir and Ritonavir by RP HPLC Method".Acta Scientific Pharmaceutical Sciences 8.6 (2024): 102-109.

Copyright

Copyright: © 2024 Varada Soujanya and Revu Baby Nalanda. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.